Verucerfont

Verucerfont is an antagonist of corticotropin-releasing factor receptor 1 (CRF1) . (In Vivo) :Post hoc analysis shows that the prototypic non-peptide CRF1 receptor antagonist NBI30775 (R121919) and Verucerfont are both significantly different from vehicle, CP-316 311, and pexacerfont (P<0.001 for all comparisons collapse across time-points) ; the latter three treatments in turn do not differ from each other. A differential effect of treatments over time is also shown by a significant treatmentxtime interaction (F[20,140]=6.4, P<0.001) . Accordingly, detailed Post hoc analysis shows that both NBI30775 and Verucerfont inhibit ACTH release throughout the following 6 h of measurement (P<0.001 vs vehicle at each time-point, and vs the respective pretreatment baseline) .